The Paola-1 Study: Olaparib And Bevacizumab For Ovarian Cancer

The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer

Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumab

PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer

PAOLA-1 Study Surgical Subset for Ovarian Cancer

The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA

Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial

Implications of PAOLA-1 in Advanced Ovarian Cancer

Targeted Oncology

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

#ESMO19: Positive Trial for Ovarian Cancer: PAOLA-1/ENGOT-ov25

Society of Gynecologic Oncology

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?

Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer

European Society for Medical Oncology (ESMO)

Maintenance Therapy in Ovarian Cancer

PARP + Maintenance Bevacizumab in Ovarian Cancer

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

EMJ

Updates in Ovarian Cancer: Frontline Maintenance

ESMO 2020 Expert Video Report on studying further advanced ovarian cancer

European Society for Medical Oncology (ESMO)

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without...